Sermorelin (GRF 1-29) | 2mg, 5mg & 10mg Research Grade Peptide

Product Overview
Sermorelin (GRF 1-29) | 2mg, 5mg & 10mg
Sermorelin is a synthetic analogue of the naturally occurring Growth Hormone Releasing Hormone (GHRH). It specifically corresponds to the amino-terminal segment (residues 1-29) of the full 44-amino acid GHRH molecule.
Research has established that this 1-29 fragment contains the full biological activity required to stimulate the pituitary gland. Unlike modified analogues (such as CJC-1295), Sermorelin retains the native pharmacokinetic profile of endogenous GHRH, characterised by a rapid onset and a short biological half-life (minutes).
This profile makes Sermorelin the primary reagent for investigating pulsatile growth hormone secretion. It allows researchers to mimic the body’s natural, episodic release patterns without the sustained receptor saturation seen with long-acting analogues.
Technical Specifications
Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Chemical Name: Growth Hormone Releasing Factor (1-29) Amide
Format: Lyophilised Cake/Powder
Purity: >99% (HPLC Verified)
Half-Life: Short (approx. 10-20 minutes)
Solubility: High (Aqueous)
Solvent: Solvent not included (Sold Separately)
Grade: Analytical Research Grade

Variant Breakdown
2mg & 5mg Vials: Standard research aliquots.
10mg Vial: High-Concentration Vial.

Note: All variants are contained within a 3ml capacity vial.

Quality AssuranceThis compound has undergone rigorous third-party analysis.
HPLC Verified: Independent analysis confirms peptide purity exceeds 99%.
Mass Spectrometry: Confirms accurate molecular weight (approx. 3358 Da) and sequence integrity.
TFA Removal: Processed via acetate exchange to remove inflammatory trifluoroacetic acid salts, ensuring high viability in sensitive cell culture applications.

Research MechanismIn laboratory settings, Sermorelin is utilised to investigate:
Pituitary Sensitivity: Assessing the responsiveness of somatotroph cells to GHRH stimulation.
Negative Feedback Loops: Studying how rapid GH pulses influence Somatostatin release (the “off switch” for growth hormone).
Sleep Architecture: Researching the correlation between GHRH signaling and the regulation of slow-wave sleep (SWS) cycles in animal models.

Safety and HandlingWARNING: This product is exclusively for laboratory research and in vitro use.
Research Only: Not intended for human consumption, diagnostic, or therapeutic use.
Handling: Wear appropriate personal protective equipment (PPE).
Storage: Store lyophilised vials in a cool, dry place. For long-term preservation, freezing at -20°C is recommended. 

Scientific References Journal of Clinical Endocrinology & Metabolism (1984) – “Growth hormone-releasing factor (1-29) is a potent stimulus for growth hormone release.” (The foundational study on the 1-29 fragment). View Article

Acta Paediatrica (1993) – “Pharmacokinetics of growth hormone-releasing factor (GRF 1-29) in humans.” (Defining the half-life profile). View Article

Neuroendocrinology (1992) – “Effects of growth hormone-releasing hormone (GHRH) on sleep and growth hormone secretion.” View Article

Peptides (2002) – “Stability of GRF(1-29)NH2 in solution: effect of pH and temperature.” View Article